The Stratified Medicine Group focuses on the following areas:
- Characterisation of a molecular group in solid cancers that represents an innate immune response to DNA damage through the STING pathway.
- Development of a biomarker for anti-angiogenic agents
- Development of a biomarker for MEKK pathway activation
- Identification of a prognostic biomarker for early prostate cancer
- Development of new cell lines for pre-clinical modelling of ovarian and prostate cancer